The Good and the Bad Fiscal Theory of the Price Level

Willem Buiter
Global Chief Economist
willem.buiter@citi.com
+1 212-816-2363

Presentation prepared for the C.D. Deshmukh Memorial Lecture at the Reserve Bank of India, 11 April 2017

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Certain products (not inconsistent with the author's published research) are available only on Citi's portals.

This presentation was approved for distribution on 7 April 2017; the disclosures in Appendix A1 are current as of the same date.
The Good and the Bad FTPL

Is a lecture on the Fiscal Theory of the Price Level “Art for Art’s Sake”?  

● Yes and No

● Yes: I love economic theory and take it very seriously:
  – Propositions and theories that are internally inconsistent must be exposed and relegated to the dustbin of intellectual history.

● No: It has direct practical policy design significance for the real world.
  – The FTPL is false theory
  – It asserts that there is no intertemporal budget constraint for the government, the central bank and the consolidated State
  – The State can pursue essentially arbitrary programs/rules/policies for public spending, taxes, monetary issuance and policy rates (non-Ricardian programs).
  – Insolvency of and default by the sovereign are never a problem: the price level will assume whatever value is required to make the value of the outstanding stock of nominal government bonds – priced at their contractual values – equal to the PDV of whatever resources the State has available for debt service.
  – This is a dangerous message to convey to any government: spend more, tax less, the price level will take care of it.
    • Japan – FTPL said to have reached PM Abe, through Prof. Koichi Hamada.
    • Brazil – FTPL influenced monetary policy debate: Lara Resende: high real interest rates caused by high nominal policy rates.
The Good and the Bad FTPL

● What the FTPL is not:

1. Unanticipated inflation or financial repression can reduce the real value of nominal public debt.

   • Inflation is always and everywhere a monetary phenomenon.
   • In modern economies with central banks issuing fiat monetary liabilities, money is ultimately a fiscal phenomenon.

● One obvious objection to the FTPL:

– I’m a Keynesian – in my view of the world money wages and the nominal prices of processed goods and services are sticky/rigid/predetermined: the general price level cannot make the required FTPL jumps.

– Sims (2011, 2016a): sticky price level is no problem. Real private consumption (and – WHB – real private investment?) can jump if the price level cannot!

– Bingo, the Fiscal Theory of the Level of Economic Activity (FTLEA)

– Unfortunately, the FTLEA suffers the same fate as the FTPL.
The Good and the Bad FTPL

- Two necessary conditions for valid dynamic general equilibrium analysis
  1. Count!
     a. Make sure the number of equations equals the number of unknowns
     b. Make sure the number of state variables equals the number of boundary conditions
  2. Think!
     a. If condition (1) is satisfied, make sure the equations can be solved
     b. If they can be solved, make sure that the resulting solution(s) make economic sense.

- The FTPL and the FTLEA fail on both counts.
The Good and the Bad FTPL

● History

  Conference: “Next Steps for the Fiscal Theory of the Price Level” at the Becker Friedman Institute for Research on Economics at the University of Chicago, 1 April, 2016.
  – Second death: Buiter (2017a,b,c).
  – Not an empirical issue: logically inconsistent theories have no empirical implications.
  – Not a disagreement about the realism of certain assumptions: if a theory is logically inconsistent, the realism or lack of it of its assumptions is irrelevant.
The Good and the Bad FTPL

● Fundamental fallacy:
  – The State does not have an IBC that has be satisfied always/identically; it only is required to be satisfied in equilibrium
  – What looks like the IBC of the State – holding with equality and with sovereign bonds valued at their contractual (free of default risk) values – is either a reflection, in equilibrium, of the IBC of the private sector (households) and/or a government (nominal) bond pricing equilibrium equation.
  – Somehow, the general price level (FTPL) or the level or real economic activity (FTLEA) sets the real value of nominal government bonds outstanding, priced at their contractual values, equal to the PDV of future State primary surpluses plus seigniorage.

● Unpleasant reality:
Either the State ensures its IBC is satisfied identically, that is, for all possible values of prices, quantities and other variables that enter into the IBC – not just in equilibrium or one of three outcomes results from the pursuit of arbitrary, non-Ricardian fiscal-financial-monetary programs (FFMPs):
  1. You satisfy the IBC of the State exactly (with equality) in equilibrium; congratulations, you have been lucky.
  2. You waste fiscal space in equilibrium. You satisfy the IBC of the State, but you have taxed too much or spent too little.
  3. You violate the IBC of the State in equilibrium. The ‘equilibrium’ isn’t an equilibrium.
The Good and the Bad FTPL

\( M \): nominal stock of central bank money
\( B \): number of short nominal government bonds held outside the central bank
\( B' \): number of short index-linked government bonds held outside the central bank
\( P \): general price level,
\( \pi = \dot{P} / P \): rate of inflation

\( i^M \): Nominal interest rate on money
\( i \): short nominal interest rate on government bonds
\( r \): short real interest rate on government bonds
\( s \): real value of primary surplus of State
\( \sigma \): real value of seigniorage

\[
\dot{M} + \dot{B} + P \dot{b} \equiv iB + Prb + i^M M - Ps
\]  \hspace{1cm} (1)

\[
\sigma \equiv \frac{\dot{M} - i^M M}{P}
\]  \hspace{1cm} (2)
The **intertemporal budget identity** of the State:

\[
\frac{B(t)}{P(t)} + b(t) \equiv \int_{t}^{\infty} e^{-\int_{t}^{v} r(u) du} \left( s(v) + \sigma(v) \right) dv + \lim_{v \to \infty} e^{-\int_{t}^{v} r(u) du} \left( \frac{B(v)}{P(v)} + b(v) \right)
\]  

\( (3) \)

The **solvency constraint** of the State: no open-ended Ponzi finance

\[
\lim_{v \to \infty} e^{-\int_{t}^{v} r(u) du} \left( \frac{B(v)}{P(v)} + b(v) \right) = \frac{1}{P(t)} \lim_{v \to \infty} \left( B(v) + P(v)b(v) \right) \leq 0
\]  

\( (4) \)

Note: solvency constraint of State is not:

\[
\lim_{v \to \infty} e^{-\int_{t}^{v} r(u) du} \left( \frac{M(v) + B(v)}{P(v)} + b(v) \right) = \frac{1}{P(t)} \lim_{v \to \infty} \left( \frac{M(v) + B(v)}{P(v)} + b(v) \right) \leq 0
\]

Reason: irredeemability of monetary base; Matters for FTS, not for FTPL/FTLEA

Equations (3) and (4) imply the **intertemporal budget constraint** of the State:

\[
\frac{B(t)}{P(t)} + b(t) \leq \int_{t}^{\infty} e^{-\int_{t}^{v} r(u) du} \left( s(v) + \sigma(v) \right) dv
\]  

\( (5) \)

FFMPs that always satisfy (5) are called **Ricardian FFMPs**
The Good and the Bad FTPL

- What happens if the State does not always pursue Ricardian FFMPs? Bond revaluation factor/contractual price discount factor makes an appearance:

\[
D(t) \left( \frac{B(t)}{P(t)} + b(t) \right) = \int_{t}^{\infty} e^{-\int_{t}^{v} r(u) du} \left( \bar{s}(v) + \bar{\sigma}(v) \right) dv
\]

\[0 \leq D \leq 1\]

Ricardian FFMPs: \( D(t) \equiv 1 \)

- Why does the FTPL/FTLEA not require (5) to hold identically – the way it is assumed to be for households?
  - State has unique revenue sources (taxes and seigniorage)? Irrelevant.
  - State isn’t optimizing? Irrelevant
  - State is myopic/not forward-looking? Irrelevant. Even if this is true, markets and/or (foreign) courts will enforce IBC of State by doing counterfactual: does (6) hold with \( D(t) = 1 \), with discount rates free of default risk, for all values of \( P \)?
The Good and the Bad FTPL

- FTPL imposes (6), but leaves out $D(t)$, despite arbitrary, non-Ricardian FFMPs:

$$\frac{B(t)}{P(t)} + b(t) = \int_{t}^{\infty} e^{-\int_{t}^{v} r(u) du} \left( \mathcal{S}(v) + \mathcal{\bar{S}}(v) \right) dv$$

(7)

FTPL hopes $P$ can do the job of $D$

*Unfortunately it cannot: 2 inconsistencies and 5 unacceptable anomalies*
The Good and the Bad FTPL

● **Inconsistency 1:**
  – The FTPL implies an overdetermined system if there is an exogenous rule for the nominal money stock.

● **Inconsistency 2**
  – If the price level is not freely flexible but predetermined, the FTPL implies either an overdetermined system or a system that is inconsistent in another way. Below we discuss Sims’s attempt to make the real and/or nominal discount factors $\int_r^{t} e^{r(u)du}$ and $\int_t^{v} e^{i(u)du}$, $v \geq t$ do the job in the FTLEA that the price level is meant to do in the FTPL.

**Is there an escape route from overdeterminacy for the FTPL?** Consider: (1) a flexible price level; (2) an exogenous nominal policy rate rule and an endogenous nominal money stock and (3) a positive stock of nominal bonds.

● **Anomaly 1.** The FTPL can generate a negative price level.

● **Anomaly 2.** There is no FTPL if all public debt is index-linked (or denominated in foreign currency).

● **Anomaly 3.** The FTPL can determine the price of phlogiston – it can determine an equilibrium price without an associated quantity.

● **Anomaly 4.** The FTPL makes as much sense as the HTPL or the ‘Mr Jones Theory of the Price Level’.

● **Anomaly 5.** When the equilibrium bond pricing equation is specified correctly – with the government bond revaluation factor - there is no FTPL.
The price level is predetermined. Can the real discount factor for the augmented primary surplus ensure that (7) holds always?

Consider the following two non-Ricardian FFMPs:

\[
\overline{s} = s(t) + \sigma(t)
\]

\[
i(t) = \delta + \pi(t)
\]

\[
\delta > 0
\]

or

\[
B(t), b(t) \geq 0
\]

\[
\overline{s} = s(t) + \sigma(t) < 0
\]

\[
i(t) = \text{anything at all}
\]

With the first of these FFMPs we have:

\[
\frac{B(t)}{P(t)} + b(t) = \frac{\overline{s}}{\delta}
\]

Equation (8) can only be satisfied by happenstance
Sims’s adds nominal long-maturity bonds (a consol/perpetuity paying on unit of money forever):

\[ P^\ell (t) = \int_{t}^{\infty} e^{-\int_{t}^{v} i(u)du} dv \]

The IBC of the State is now:

\[
\frac{B(t)}{P(t)} + b(t) + \frac{B^\ell (t)}{P(t)} \int_{t}^{\infty} e^{-\int_{t}^{v} i(u)du} dv = \int_{t}^{\infty} e^{-\int_{t}^{v} r(u)du} \left( \overline{s}(v) + \overline{\sigma}(v) \right) dv
\]

Consider the following two non-Ricardian FFMPs:

\[
\overline{s} + e^{-\int_{t}^{v} \pi(u)du} \frac{B^\ell (t)}{P(t)} = s(v) + \sigma(v), \quad v \geq t
\]

\[ i(t) = \text{anything at all} \]

or

\[ B(t), b(t), B^\ell (t) \geq 0 \]

\[ \overline{s} = s(t) + \sigma(t) < 0 \]

\[ i(t) = \text{anything at all} \]

With the first of the non-Ricardian FFMPs we return to equation (8). The second is always inconsistent.
The Fiscal Theory of Seigniorage (Buiter (2007, 2014))
- Central banking is (most of the time) profitable
- The central government Treasury/MoF is the beneficial owner of the central bank
- Why is central banking profitable?
  - \( i > i^M \) except at ELB
  - Irredeemability of central bank money.

Equivalent representation of IBC of State (only short nominal government bonds for simplicity):

\[
\frac{M(t)}{P(t)} + B(t) = \int_t^\infty e^{-\int_t^v r(u)du} \left( s(v) + \frac{(i(v) - i^M(v))M(v)}{P(v)} \right)dv + \lim_{v \to \infty} e^{-\int_t^v r(u)du} \left( \frac{M(v) + B(v)}{P(v)} \right)
\]

With the solvency constraint in equation (4), this becomes:
The Good and the Bad FTPL

\[
\frac{M(t) + B(t)}{P(t)} \leq \int_t^\infty e^{-\int_t^v r(u) du} \left[ s(v) + \frac{(i(v) - i^M(v))M(v)}{P(v)} \right] dv + \lim_{v \to \infty} e^{-\int_t^v r(u) du} \frac{M(v)}{P(v)}
\]

\[
= \int_t^\infty e^{-\int_t^v r(u) du} \left[ s(v) + \frac{(i(v) - i^M(v))M(v)}{P(v)} \right] dv + \frac{1}{P(t)} \lim_{v \to \infty} e^{-\int_t^v i^M(u) du} M(v)
\]

So at the ELB this becomes:

\[
\frac{M(t) + B(t)}{P(t)} \leq \int_t^\infty e^{-\int_t^v r(u) du} s(v) dv + \frac{1}{P(t)} \lim_{v \to \infty} e^{-\int_t^v i^M(u) du} M(v)
\]

So helicopter money drops work (boost nominal demand) even if the economy is in a permanent liquidity trap) if you boost the money supply at time \( t \) and subsequently grow it at a proportional rate \( i^M \).
Conclusion

- The FTPL and FTLEA are false theories. It is time to re-bury them.

- The Fiscal Theory of Seigniorage asserts that balance sheet expansion/contraction by the central bank always has a fiscal dimension. In 2015 the Fed paid about $97.7bn in regular profits to the US Treasury. In addition, the US Congress raided the reserves of the Regional Reserve Banks to the tune of $19.3bn – to help fund the Fixing America’s Surface Transportation Act (FAST Act!).

- The FRS is very much alive.
References


Appendix A-1

Analyst Certification

The research analysts primarily responsible for the preparation and content of this research report are either (i) designated by “AC” in the author block or (ii) listed in bold alongside content which is attributable to that analyst. If multiple AC analysts are designated in the author block, each analyst is certifying with respect to the entire research report other than (a) content attributable to another AC certifying analyst listed in bold alongside the content and (b) views expressed solely with respect to a specific issuer which are attributable to another AC certifying analyst identified in the price charts or rating history tables for that issuer shown below. Each of these analysts certify, with respect to the sections of the report for which they are responsible: (1) that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc. and its affiliates; and (2) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Disclosure for investors in the Republic of Turkey: Under Capital Markets Law of Turkey (Law No: 6362), the investment information, comments and advices given herein are not part of investment advisory activity. Investment advisory services are provided by authorized institutions to persons and entities privately by considering their risk and return preferences. Whereas the comments and advices included herein are of general nature. Therefore, they may not fit to your financial situation and risk and return preferences. For this reason, making an investment decision only by relying on the information given herein may not give rise to results that fit your expectations. Furthermore, Citi Research is a division of Citigroup Global Markets Inc. (the “Firm”), which does and seeks to do business with companies and/or trades on securities covered in this research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report.

Analysts’ compensation is determined by Citi Research management and Citigroup’s senior management and is based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates (the “Firm”). Compensation is not linked to specific transactions or recommendations. Like all Firm employees, analysts receive compensation that is impacted by overall Firm profitability which includes investment banking, sales and trading, and principal trading revenues. One factor in equity research analyst compensation is arranging corporate access events between institutional clients and the management teams of covered companies. Typically, company management is more likely to participate when the analyst has a positive view of the company.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers’ financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm’s disclosure website at https://www.citivelocity.com/cvr eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Pursuant to the Market Abuse Regulation a history of all Citi Research recommendations published during the preceding 12-month period can be
accessed via Citi Velocity (https://www.citivelocity.com/cv2) or your standard distribution portal. Historical disclosures (for up to the past three years) will be provided upon request.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

<table>
<thead>
<tr>
<th>Legal Entity</th>
<th>Analyst Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citigroup Global Markets Inc</td>
<td>Willem Buiter</td>
</tr>
</tbody>
</table>

OTHER DISCLOSURES

Any price(s) of instruments mentioned in recommendations are as of the prior day’s market close on the primary market for the instrument, unless otherwise stated.

European regulations require that where a recommendation differs from any of the author’s previous recommendations concerning the same financial instrument or issuer that has been published during the preceding 12-month period that the change(s) and the date of that previous recommendation are indicated. Please refer to the trade history in the published research or contact the research analyst.

European regulations require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research’s Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

The proportion of all Citi Research fundamental research recommendations that were the equivalent to “Buy,” “Hold,” “Sell” at the end of each quarter over the prior 12 months (with the % of these that had received investment firm services from Citi in the prior 12 months shown in brackets) is as follows: Q4 2016 Buy 31% (71%), Hold 45% (64%), Sell 24% (58%); Q3 2016 Buy 32% (68%), Hold 44% (64%), Sell 24% (61%); Q2 2016 Buy 31% (68%), Hold 45% (63%), Sell 24% (61%); Q1 2016 Buy 31% (67%), Hold 45% (63%), Sell 24% (61%).

SECURITIES RECOMMENDED, OFFERED, OR SOLD BY THE FIRM: (i) ARE NOT INSURED BY THE FEDERAL DEPOSIT INSURANCE CORPORATION; (ii) ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF ANY INSURED DEPOSITORY INSTITUTION (INCLUDING CITIBANK); AND (iii) ARE SUBJECT TO INVESTMENT RISKS, INCLUDING THE POSSIBLE LOSS OF THE PRINCIPAL AMOUNT INVESTED. THE PRODUCT IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED AS AN OFFER OR SOLICITATION FOR THE PURCHASE OR SALE OF A SECURITIES. ANY DECISION TO PURCHASE SECURITIES MENTIONED IN THE PRODUCT MUST TAKE INTO...
account existing public information on such security or any registered prospectus. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm’s research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental equity or credit research report, it is the intention of Citi Research to provide research coverage of the covered issuers, including in response to news affecting the issuer. For non-fundamental research reports, Citi Research may not provide regular updates to the views, recommendations and facts included in the reports. Notwithstanding that Citi Research maintains coverage on, makes recommendations concerning or discusses issuers, Citi Research may be periodically restricted from referencing certain issuers due to legal or policy reasons. Citi Research may provide different research products and services to different classes of customers (for example, based upon long-term or short-term investment horizons) that may lead to differing conclusions or recommendations that could impact the price of a security contrary to the recommendations in the alternative research product, provided that each is consistent with the rating system for each respective product.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

### Important Disclosures for Bell Potter Customers

Bell Potter is making this Product available to its clients pursuant to an agreement with Citigroup Global Markets Australia Pty Limited. Neither Citigroup Global Markets Australia Pty Limited nor any of its affiliates has made any determination as to the suitability of the information provided herein and clients should consult with their Bell Potter financial advisor before making any investment decision.

### The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by.

The Product is made available in **Australia** through Citigroup Global Markets Australia Pty Limited. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. Citigroup Global Markets Australia Pty Limited is not an Authorised Deposit-Taking Institution under the Banking Act 1959, nor is it regulated by the Australian Prudential Regulation Authority. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários ("CVM"), BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBIMA – Associação Brasileira das Entidades dos Mercados Financeiro e de Capitais. Av. Paulista, 1111 - 14º andar(parque) - CEP: 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100,
The Product is available in Chile through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros, Agustinas 975, piso 2, Santiago, Chile. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG (“CGMD”), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in India by Citigroup Global Markets India Limited (CGM), which is regulated by the Securities and Exchange Board of India (SEBI), as a Research Analyst (SEBI Registration No. INH000004383). CGM is also actively involved in the business of merchant banking, stock brokerage, and depository participant, in India, and is registered with SEBI in this regard. CGM's registered office is at 1202, 12th Floor, FICG, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051. CGM's Corporate Identity Number is U99999MH2000PTC126657, and its contact details are: Tel:+910226175999 Fax:+9102261759961.

The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Israel through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'atarba'ah St, Tel Aviv, Israel. The Product is made available in Italy by Citigroup Global Markets Limited, which is authorised by the FCA and regulated by the FCA and the PRA. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in Japan by Citigroup Global Markets Japan Inc. (“CGMJ”), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Maranouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. It is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wqFundMgr/DISFundMgrAnalyList.xml&divisionId=MDIS03002020020000&serviceId=SDIS03002020000. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) (“CGMM”) to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from or in connection with, the Product. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex (“Accival”) which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available to ‘wholesale clients’ only as defined by s3C(1) of the Financial Advisers Act 2008 (‘FAA’) through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundirgar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the Philippines through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is
regulated by The Bangko Sentral ng Pilipinas. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through AO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd. (“CGMSPL”), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd (“CSL”) to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in the Republic of China through Citigroup Global Markets Taiwan Securities Company Ltd. (“CGMTS”), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited (“CSTL”), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 399 Interchange 21 Building, 18th Floor, Sukhumvit Road, Klongtoey Nua, Wattana, Bangkok 10110, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the U.A.E, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch (“CGML”), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in the United Kingdom by Citigroup Global Markets Limited, which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA. This material may relate to investments or services of a person outside of the UK or to other matters which are not authorised by the PRA nor regulated by the FCA and the PRA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is authorised by the PRA and regulated by the FCA and the PRA.
The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes the Firm's estimates, data from company reports and feeds from Thomson Reuters. The printed and printable version of the research report may not include all the information (e.g., certain financial summary information and comparable company data) that is linked to the online version available on the Firm's proprietary electronic distribution platforms.

© 2017 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. The research data in this report is not intended to be used for the purpose of (a) determining the price or amounts due in respect of one or more financial products or instruments and/or (b) measuring or comparing the performance of a financial product or a portfolio of financial instruments, and any such use is strictly prohibited without the prior written consent of Citi Research. Any unauthorized use, duplication, redistribution or disclosure of this report (the “Product”), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in any way form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST